1L	First-line
2L	Second-line
3L+	Third-line or later
BV	Brentuximab vedotin
CAR	Chimeric antigen receptor
CNS	Central nervous system
DLBCL	Diffuse large B-cell lymphoma
ECOG	Eastern Cooperative Oncology Group
EHR	Electronic health record
GemOx	Gemcitabine + oxaliplatin
HSCT	Hematopoietic stem cell transplant
IPI	International Prognostic Index
IQR	Interquartile range
KM	Kaplan–Meier
LOT	Line of therapy
M/U	Missing/unknown
NHL	Non-Hodgkin lymphoma
OS	Overall survival
Pola-BR	Pola-bendamustine + rituximab
Pola-R-CHP	Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone
R2	Lenalidomide and rituximab
R/R	Relapsed/refractory
R-CHOP	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
rw	Real-world
SOC	Standard of care
TTNTD	Time to next treatment or death